Apatinib Case Study Uncovers Potential Mesothelioma Treatment
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma.
Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment.
After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival.
“I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality of life was g...
Source: Asbestos and Mesothelioma News - January 31, 2019 Category: Environmental Health Authors: Daniel King Source Type: news
Pfizer's cut-price version of Avastin wins EU panel greenlight
A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin. (Source: Reuters: Health)
Source: Reuters: Health - December 14, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV ™ (bevacizumab)
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab). (Source: World Pharma News)
Source: World Pharma News - December 14, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Roche wins key lung cancer combo approval
Roche Holding ’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 7, 2018 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - December 7, 2018 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2018 Category: Pharmaceuticals Source Type: news
FDA Approves Genentech ’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
South San Francisco, CA -- December 6, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 6, 2018 Category: Drugs & Pharmacology Source Type: news
Capecitabine + bevacizumab in CRC: small benefit, high cost in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news
Avastin: updated statement on its use for the treatment of wet AMD
The recent judicial review ruling finds the use of Avastin (bevacizumab) in the NHS for the treatment of wet AMD to be lawful. Whilst we recognise the financial savings that could be made by switching (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 22, 2018 Category: Drugs & Pharmacology Source Type: news
